Median Changes in Aspartate-to-Platelet Ratio Index Score on the Multiplicative Scale Associated With Time on Combination Antiretroviral Therapy Among Protease Inhibitors or Nonnucleoside Reverse Transcriptase Users Estimated by Linear Regression With Generalized Estimating Equations
| . | Model 1a . | Model 2b . |
|---|---|---|
| Exp(β) (95% CI) . | Exp(β) (95% CI) . | |
| Age (5 y) at cohort entry | 1.00 (.96, 1.04) | 1.00 (.96, 1.04) |
| Female | 0.90 (.79, 1.02) | 0.90 (.79, 1.02) |
| Time since hepatitis C virus infection at cohort (5 y)c | 1.04 (1.01, 1.07) | 1.04 (1.01, 1.07) |
| CD4 cell count at the previous study visit (100 cells/mL) | 0.99 (.98, 1.00) | 0.99 (.98, 1.00) |
| Undetectable viral load(<50 copies/mL) | 0.98 (.91, 1.06) | 0.98 (.91, 1.06) |
| Alcohol use in the past 6 mo | 1.03 (.95, 1.11) | 1.03 (.95, 1.11) |
| TDF/FTC backbone at cohort entry | 1.32 (1.14, 1.50) | 1.44 (1.20, 1.68) |
| cART initiated with NNRTI | 1.00 (.84, 1.16) | 1.00 (.84, 1.16) |
| Time on cART among PI users (5 y)d | 1.11 (1.01, 1.21) | NA |
| Time on cART among NNRTI users (5 y)d | 1.07 (.99, 1.14) | NA |
| Time on cART among PI-ABC/3TC users (5 y)e | NA | 1.16 (1.04, 1.29) |
| Time on cART among PI-TDF/FTC users (5 y)e | NA | 1.08 (.97, 1.19) |
| Time on cART among NNRTI-ABC/3TC users (5 y)e | NA | 1.11 (1.02, 1.20) |
| Time on cART among NNRTI-TDF/FTC users (5 y)e | NA | 1.03 (.93, 1.12) |
| . | Model 1a . | Model 2b . |
|---|---|---|
| Exp(β) (95% CI) . | Exp(β) (95% CI) . | |
| Age (5 y) at cohort entry | 1.00 (.96, 1.04) | 1.00 (.96, 1.04) |
| Female | 0.90 (.79, 1.02) | 0.90 (.79, 1.02) |
| Time since hepatitis C virus infection at cohort (5 y)c | 1.04 (1.01, 1.07) | 1.04 (1.01, 1.07) |
| CD4 cell count at the previous study visit (100 cells/mL) | 0.99 (.98, 1.00) | 0.99 (.98, 1.00) |
| Undetectable viral load(<50 copies/mL) | 0.98 (.91, 1.06) | 0.98 (.91, 1.06) |
| Alcohol use in the past 6 mo | 1.03 (.95, 1.11) | 1.03 (.95, 1.11) |
| TDF/FTC backbone at cohort entry | 1.32 (1.14, 1.50) | 1.44 (1.20, 1.68) |
| cART initiated with NNRTI | 1.00 (.84, 1.16) | 1.00 (.84, 1.16) |
| Time on cART among PI users (5 y)d | 1.11 (1.01, 1.21) | NA |
| Time on cART among NNRTI users (5 y)d | 1.07 (.99, 1.14) | NA |
| Time on cART among PI-ABC/3TC users (5 y)e | NA | 1.16 (1.04, 1.29) |
| Time on cART among PI-TDF/FTC users (5 y)e | NA | 1.08 (.97, 1.19) |
| Time on cART among NNRTI-ABC/3TC users (5 y)e | NA | 1.11 (1.02, 1.20) |
| Time on cART among NNRTI-TDF/FTC users (5 y)e | NA | 1.03 (.93, 1.12) |
Abbreviations: ABC/3TC, abacavir/lamivudine; APRI, aspartate-to-platelet ratio index; cART, combination antiretroviral therapy; CI, confidence interval; NA, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF/FTC, tenofovir/emtricitabine.
a Model 1: E[ln(APRI)] = β0 + βiNNRTI + β2Years + β3NNRTI × Years + ∑ βjcovariatesj.
b Model 2: E[ln(APRI)] = β0 + β1NNRTI + β2Years + β3NNRTI × Years + β4TDF/FTC + β5TDF/FTC × Years + ∑ βjcovariatesj.
c Based on the date of hepatitis C virus (HCV) seroconversion, if known, or year of first injection drug use or blood product exposure as a proxy of HCV infection.
d Represents the rate of change in APRI score over 5 years. Obtained with the interaction term between NNRTI use and time since cART initiation.
e Represents the rate of change in APRI score over 5 years. Obtained with the interaction terms between NNRTI use and time since cART initiation and between TDF/FTC use and time since cART initiation from the equation.
Median Changes in Aspartate-to-Platelet Ratio Index Score on the Multiplicative Scale Associated With Time on Combination Antiretroviral Therapy Among Protease Inhibitors or Nonnucleoside Reverse Transcriptase Users Estimated by Linear Regression With Generalized Estimating Equations
| . | Model 1a . | Model 2b . |
|---|---|---|
| Exp(β) (95% CI) . | Exp(β) (95% CI) . | |
| Age (5 y) at cohort entry | 1.00 (.96, 1.04) | 1.00 (.96, 1.04) |
| Female | 0.90 (.79, 1.02) | 0.90 (.79, 1.02) |
| Time since hepatitis C virus infection at cohort (5 y)c | 1.04 (1.01, 1.07) | 1.04 (1.01, 1.07) |
| CD4 cell count at the previous study visit (100 cells/mL) | 0.99 (.98, 1.00) | 0.99 (.98, 1.00) |
| Undetectable viral load(<50 copies/mL) | 0.98 (.91, 1.06) | 0.98 (.91, 1.06) |
| Alcohol use in the past 6 mo | 1.03 (.95, 1.11) | 1.03 (.95, 1.11) |
| TDF/FTC backbone at cohort entry | 1.32 (1.14, 1.50) | 1.44 (1.20, 1.68) |
| cART initiated with NNRTI | 1.00 (.84, 1.16) | 1.00 (.84, 1.16) |
| Time on cART among PI users (5 y)d | 1.11 (1.01, 1.21) | NA |
| Time on cART among NNRTI users (5 y)d | 1.07 (.99, 1.14) | NA |
| Time on cART among PI-ABC/3TC users (5 y)e | NA | 1.16 (1.04, 1.29) |
| Time on cART among PI-TDF/FTC users (5 y)e | NA | 1.08 (.97, 1.19) |
| Time on cART among NNRTI-ABC/3TC users (5 y)e | NA | 1.11 (1.02, 1.20) |
| Time on cART among NNRTI-TDF/FTC users (5 y)e | NA | 1.03 (.93, 1.12) |
| . | Model 1a . | Model 2b . |
|---|---|---|
| Exp(β) (95% CI) . | Exp(β) (95% CI) . | |
| Age (5 y) at cohort entry | 1.00 (.96, 1.04) | 1.00 (.96, 1.04) |
| Female | 0.90 (.79, 1.02) | 0.90 (.79, 1.02) |
| Time since hepatitis C virus infection at cohort (5 y)c | 1.04 (1.01, 1.07) | 1.04 (1.01, 1.07) |
| CD4 cell count at the previous study visit (100 cells/mL) | 0.99 (.98, 1.00) | 0.99 (.98, 1.00) |
| Undetectable viral load(<50 copies/mL) | 0.98 (.91, 1.06) | 0.98 (.91, 1.06) |
| Alcohol use in the past 6 mo | 1.03 (.95, 1.11) | 1.03 (.95, 1.11) |
| TDF/FTC backbone at cohort entry | 1.32 (1.14, 1.50) | 1.44 (1.20, 1.68) |
| cART initiated with NNRTI | 1.00 (.84, 1.16) | 1.00 (.84, 1.16) |
| Time on cART among PI users (5 y)d | 1.11 (1.01, 1.21) | NA |
| Time on cART among NNRTI users (5 y)d | 1.07 (.99, 1.14) | NA |
| Time on cART among PI-ABC/3TC users (5 y)e | NA | 1.16 (1.04, 1.29) |
| Time on cART among PI-TDF/FTC users (5 y)e | NA | 1.08 (.97, 1.19) |
| Time on cART among NNRTI-ABC/3TC users (5 y)e | NA | 1.11 (1.02, 1.20) |
| Time on cART among NNRTI-TDF/FTC users (5 y)e | NA | 1.03 (.93, 1.12) |
Abbreviations: ABC/3TC, abacavir/lamivudine; APRI, aspartate-to-platelet ratio index; cART, combination antiretroviral therapy; CI, confidence interval; NA, not applicable; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TDF/FTC, tenofovir/emtricitabine.
a Model 1: E[ln(APRI)] = β0 + βiNNRTI + β2Years + β3NNRTI × Years + ∑ βjcovariatesj.
b Model 2: E[ln(APRI)] = β0 + β1NNRTI + β2Years + β3NNRTI × Years + β4TDF/FTC + β5TDF/FTC × Years + ∑ βjcovariatesj.
c Based on the date of hepatitis C virus (HCV) seroconversion, if known, or year of first injection drug use or blood product exposure as a proxy of HCV infection.
d Represents the rate of change in APRI score over 5 years. Obtained with the interaction term between NNRTI use and time since cART initiation.
e Represents the rate of change in APRI score over 5 years. Obtained with the interaction terms between NNRTI use and time since cART initiation and between TDF/FTC use and time since cART initiation from the equation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
